Mirum Pharmaceuticals, Inc. (MIRM)
86.01
+4.66
(+5.73%)
USD |
NASDAQ |
Oct 09, 16:00
85.90
-0.12
(-0.13%)
Pre-Market: 20:00
Mirum Pharmaceuticals Cash from Operations (Quarterly) : -44.25M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -44.25M |
| March 31, 2026 | -228.76M |
| December 31, 2025 | 6.067M |
| September 30, 2025 | 39.68M |
| June 30, 2025 | 12.04M |
| March 31, 2025 | -1.961M |
| December 31, 2024 | -5.068M |
| September 30, 2024 | 3.984M |
| June 30, 2024 | -3.803M |
| March 31, 2024 | 15.21M |
| December 31, 2023 | -16.62M |
| September 30, 2023 | -18.22M |
| June 30, 2023 | -2.331M |
| March 31, 2023 | -33.77M |
| December 31, 2022 | -34.27M |
| Date | Value |
|---|---|
| September 30, 2022 | -26.02M |
| June 30, 2022 | -20.17M |
| March 31, 2022 | -39.67M |
| December 31, 2021 | -33.15M |
| September 30, 2021 | -34.20M |
| June 30, 2021 | -40.20M |
| March 31, 2021 | -25.21M |
| December 31, 2020 | -36.28M |
| September 30, 2020 | -17.45M |
| June 30, 2020 | -16.99M |
| March 31, 2020 | -18.35M |
| December 31, 2019 | -13.70M |
| September 30, 2019 | -15.22M |
| June 30, 2019 | -8.017M |
| March 31, 2019 | -2.426M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Incyte Corp. | 507.66M |
| Insmed, Inc. | -88.83M |
| Galectin Therapeutics, Inc. | -2.439M |
| Kodiak Sciences, Inc. | -46.24M |
| Praxis Precision Medicines, Inc. | -77.19M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -159.99M |
| Cash from Financing (Quarterly) | 211.44M |
| Free Cash Flow | -263.74M |
| Free Cash Flow Per Share (Quarterly) | -1.093 |
| Free Cash Flow to Equity (Quarterly) | -508.44M |
| Free Cash Flow to Firm (Quarterly) | -66.59M |
| Free Cash Flow Yield | -5.31% |